Last reviewed · How we verify
IgY
IgY is a polyclonal immunoglobulin Y (chicken antibody) therapeutic that targets and neutralizes Pseudomonas aeruginosa virulence factors and biofilm components in the respiratory tract.
IgY is a polyclonal immunoglobulin Y (chicken antibody) therapeutic that targets and neutralizes Pseudomonas aeruginosa virulence factors and biofilm components in the respiratory tract. Used for Cystic fibrosis with chronic Pseudomonas aeruginosa respiratory infection.
At a glance
| Generic name | IgY |
|---|---|
| Also known as | PsAer-IgY |
| Sponsor | Mukoviszidose Institut gGmbH |
| Drug class | Polyclonal immunoglobulin Y (IgY) therapeutic |
| Target | Pseudomonas aeruginosa lipopolysaccharide and surface antigens |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
IgY antibodies are derived from immunized chickens and recognize multiple epitopes on P. aeruginosa lipopolysaccharide and other surface antigens. By binding these bacterial components, IgY prevents bacterial adhesion, reduces biofilm formation, and enhances clearance of the pathogen in cystic fibrosis airways. This polyclonal approach provides broad coverage against diverse P. aeruginosa strains.
Approved indications
- Cystic fibrosis with chronic Pseudomonas aeruginosa respiratory infection
Common side effects
- Respiratory adverse events (cough, bronchospasm)
- Gastrointestinal events
- Hypersensitivity reactions
Key clinical trials
- Evaluation of IgY Antibody Efficacy in Egg Yolk Against Helicobacter Pylori in Bacterial Elimination and Clinical Symptoms Improvement of Gastrointestinal Patients (PHASE2)
- Assessing the Safety of an IGY Supplement on the Gut Microbiome (PHASE1)
- Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients
- Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19) (PHASE1)
- Effectiveness of GastimunHp Plus in Supporting the Treatment of Peptic Ulcer Disease With Helicobacter Pylori Infection (NA)
- Effect of Chicken Egg Antibody (IgY) on Patients With Chronic Gastritis (NA)
- The Influence of IgY Max on Inflammatory Markers and the Gut Microbiome (PHASE1, PHASE2)
- Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IgY CI brief — competitive landscape report
- IgY updates RSS · CI watch RSS
- Mukoviszidose Institut gGmbH portfolio CI